The ketamine therapy landscape has expanded rapidly, creating a confusing marketplace of options for depression sufferers. From luxury IV infusion centers charging $500 per session to telehealth platforms mailing sublingual tablets, patients face critical decisions about cost, safety, and efficacy.

Intravenous (IV) Ketamine: The Gold Standard

IV infusion remains the most established and rapid-acting delivery method. Administered directly into the bloodstream over 40 minutes, IV ketamine achieves precise dosing with 100% bioavailability. Clinicians can adjust doses mid-infusion based on patient response, and the rapid onset allows immediate monitoring of effects.

IV clinics typically charge $400-800 per session, with initial series requiring 6 sessions over 2-3 weeks. This cost barrier excludes many patients, though some clinics offer sliding scales. The medical supervision provided—continuous monitoring of blood pressure, oxygen saturation, and mental status—represents significant safety advantages.

Esketamine (Spravato): The Regulated Alternative

In 2019, the FDA approved esketamine nasal spray (Spravato) specifically for treatment-resistant depression. As the S-enantiomer of ketamine, esketamine provides a standardized, pharmaceutical-grade option covered by many insurance plans. Administration occurs in certified medical offices, with patients monitored for two hours post-dose.

The nasal delivery provides intermediate bioavailability—less than IV but more than oral routes. Treatment protocols require twice-weekly dosing for four weeks, then weekly, then biweekly maintenance. This frequent office visit requirement proves burdensome for working patients but ensures regular clinical contact.

Oral and Sublingual Ketamine: The Accessibility Frontier

Compounding pharmacies and telehealth platforms increasingly offer oral tablets, sublingual lozenges, and troches. These methods offer dramatically lower costs ($75-200 monthly) and eliminate travel requirements. However, bioavailability drops to approximately 20-30% for oral and 30-50% for sublingual, requiring higher doses and producing less predictable effects.

The at-home model raises safety concerns. While ketamine demonstrates excellent safety profiles in medical settings, unsupervised use carries risks of blood pressure elevation, falls, and psychological distress. Some platforms require virtual sitters or provide emergency contact protocols.

Comparative Efficacy

Direct head-to-head comparisons between delivery methods remain limited. IV ketamine boasts the longest clinical track record and most rapid onset, making it preferred for acutely suicidal patients. Esketamine’s FDA approval required demonstrating superiority over placebo in treatment-resistant populations. Oral formulations show promise but lack the robust randomized trial data of other methods.

Many patients eventually combine approaches—using IV ketamine for initial induction and transitioning to oral maintenance. This hybrid model attempts to balance efficacy with sustainability.

Choosing the Right Option

Selection depends on multiple factors: severity of depression, financial resources, geographic access, and personal preference regarding dissociative experiences. Severe, treatment-resistant cases with acute suicidal ideation warrant IV ketamine’s rapidity. Patients requiring insurance coverage may find esketamine the only feasible option.

Safety Red Flags

Regardless of delivery method, certain provider characteristics indicate quality: psychiatric evaluation before treatment, informed consent processes, integration support, and clear emergency protocols. Avoid providers promising guaranteed cures, offering unlimited dosing without assessment, or lacking medical oversight.